Serine/threonine-protein kinase PLK1, also known as polo-like kinase 1 (PLK-1) or serine/threonine-protein kinase 13 (STPK13), is an enzyme that in humans is encoded by the PLK1 (polo-like kinase 1) gene. PLK1 (Polo-like kinase 1) inhibitors are a class of drugs designed to target and inhibit the activity of the protein kinase PLK1. PLK1 is a key regulator of cell division and is involved in various stages of the cell cycle, including mitosis (cell division) and cytokinesis (cell cleavage). It plays a crucial role in ensuring proper cell division and genomic stability. The mechanism of action of PLK1 inhibitors involves disrupting the normal functioning of PLK1, leading to cell cycle arrest and ultimately inducing cell death (apoptosis). PLK1 Inhibitors are used in the potential treatment of acute myelogenous leukemia, leukemia, adrenal diseases, endocrine gland neoplasms, genital diseases, ovarian cancers, carcinoma, digestive system disorders, immunoproliferative disorders, neutropenia, pancreatic diseases, breast diseases, colorectal neoplasms, and liver cancers to name a few. Moreover, the increasing prevalence of ovarian cancers, leukemia, lymphoma, and increasing R&D investments in cancer research are the key drivers for the PLK1 Inhibitors market. For instance, according to World Cancer Research Fund 2020, an estimated 18.1 million cancer cases around the world and 4,74,519 new cases of leukemia in 2020. The global cancer burden is expected to be 28.4 million cases in 2040, which is a 47% rise from 2020. Moreover, the development of novel molecules by many market players is coming up to overcome challenges in therapy. For instance, Oncoheroes Biosciences Volasertib (NBL-001) for the treatment of Ovarian cancer is in the various stages of clinical studies.
Key Market Developments:
- In July 2023, Onconova Therapeutics conducted phase 2 clinical studies for its Estybon (Rigosertib) for the indication of Epidermolysis Bullosa.
Drugs under the Pipeline for PLK1 Inhibitors:
- Estybon (Rigosertib)
- Volasertib (NBL-001)
- BI2536
- Onvansertib (PCM-075)
- SF1126
- TKM-PLK1
- Cafusertib
- Plogosertib (CYC140)
- BAL0891
- GSK461364
- MK-1496
- TAK-960
Clinical Activity and Developments of PLK1 Inhibitors:
Till July 2023, more than 10 companies have approximately 12 molecules targeting the many cancers. For these molecules, more than 15 clinical trials are being conducted and the majority are in phase-1, and phase-2 clinical trials by players across the globe. For instance,
- In April 2021, Boehringer Ingelheim completed phase 1/2a, a trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intravenous BI 6727 (Volasertib) as monotherapy or in combination with subcutaneous Cytarabine in patients with acute myeloid leukemia.
|
Molecule Name |
Number of Studies |
|
Estybon (Rigosertib) |
37 |
|
Volasertib (NBL-001) |
27 |
|
BI2536 |
11 |
|
Onvansertib (PCM-075) |
11 |
|
SF1126 |
4 |
Target Indication Analysis of PLK1 Inhibitors
The molecules such as Volasertib are under development by Boehringer Ingelheim in global collaboration with Oncoheroes Biosciences for the indication of Rhabdomyosarcoma in phase 1, Myelodysplastic syndromes, non-small cell lung cancer, Ovarian cancer in phase 2 and Acute myeloid leukemia in phase 3 clinical trial. Moreover, Onconova Therapeutics molecule Rigosertib for Adenocarcinoma in phase 1, Acute myeloid leukemia, Malignant melanoma, Myelodysplastic syndromes, non-small cell lung cancer, squamous cell cancer in phase 2 and for chronic myelomonocytic leukemia is in phase 3 clinical development.
Regional Analysis
PLK1 Inhibitors Market
PLK1 Inhibitors have been identified as potential therapeutic candidates for various acute myelogenous leukemia, adrenal diseases, endocrine gland neoplasms, and genital diseases. The Rising prevalence of leukemia, carcinoma, and other cancers in the USA population was relatively high compared to other countries; this is projected to create an opportunity for the future and burgeon the growth of the PLK1 Inhibitors market. For instance, according to the American Society of Clinical Oncology (ASCO) 2023, an estimated 20,380 people of all ages including 11,410 men and boys and 8,970 women and girls in the US diagnosed with acute lymphoblastic leukemia. Moreover, with the increasing geriatric population, increased R&D activity, and government reimbursement policies, modern diagnostic centers are expected to create lucrative opportunities for the PLK1 Inhibitors market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Onconova Therapeutics molecule Rigosertib is under development for the indication of adenocarcinoma in phase 1, and acute myeloid leukemia in phase 2.
Major market players include Onconova, Oncoheroes, and Boehringer Ingelheim among the few are few leading market players.
acute myelogenous leukemia, leukemia, adrenal diseases, endocrine gland neoplasms, genital diseases, and ovarian cancers to name a few are major indications for PLK1 Inhibitors.
There are a total of 12 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.
- Onconova
- Oncoheroes
- Boehringer Ingelheim
- Cardiff Oncology
- SignalRx
- Arbutus
- Jiangsu Hansoh Pharma
- Cyclacel
- SillaJen
- GSK
- Merck (MSD)
- Takeda